A medication that inhibits amyloid production may work in the variant with increased amyloid production however may be damaging in the alternative with decreased amyloid production. It is also possible that patients with one variation have a higher risk of side results, while that risk is much lower with other variations. The next action for the research study group is to show that the Alzheimers versions do certainly react in a different way to medications, so that we can deal with everyone with suitable medicines in the future.Reference: “Cerebrospinal fluid proteomics in patients with Alzheimers illness exposes 5 molecular subtypes with unique genetic risk profiles” by Betty M. Tijms, Ellen M. Vromen, Olav Mjaavatten, Henne Holstege, Lianne M. Reus, Sven van der Lee, Kirsten E. J. Wesenhagen, Luigi Lorenzini, Lisa Vermunt, Vikram Venkatraghavan, Niccoló Tesi, Jori Tomassen, Anouk den Braber, Julie Goossens, Eugeen Vanmechelen, Frederik Barkhof, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, Charlotte E. Teunissen, Frode S. Berven and Pieter Jelle Visser, 9 January 2024, Nature Aging.DOI: 10.1038/ s43587-023-00550-7.
A medication that prevents amyloid production might work in the variation with increased amyloid production however might be harmful in the alternative with decreased amyloid production. It is likewise possible that clients with one variation have a greater risk of side results, while that danger is much lower with other variations. The next step for the research team is to show that the Alzheimers variations do indeed react differently to medicines, so that we can treat everyone with appropriate medicines in the future.Reference: “Cerebrospinal fluid proteomics in clients with Alzheimers illness reveals five molecular subtypes with unique genetic threat profiles” by Betty M. Tijms, Ellen M. Vromen, Olav Mjaavatten, Henne Holstege, Lianne M. Reus, Sven van der Lee, Kirsten E. J. Wesenhagen, Luigi Lorenzini, Lisa Vermunt, Vikram Venkatraghavan, Niccoló Tesi, Jori Tomassen, Anouk den Braber, Julie Goossens, Eugeen Vanmechelen, Frederik Barkhof, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, Charlotte E. Teunissen, Frode S. Berven and Pieter Jelle Visser, 9 January 2024, Nature Aging.DOI: 10.1038/ s43587-023-00550-7.
